Analytical Data
-
基因名
HLA-A*24:02&B2M&WT-1(TYSPALNKMF) Monomer
- Application
-
别名
HLA-A*2402 & B2M & WT-1 (CYTWNQMNL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59600.1 (G25-T305)&P61769
-
表达区间
AAA59600.1 (G25-T305)&P61769 (I21-M119)&CYTWNQMNL
-
分子量
39-41 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*24:02, B2M, and the WT-1 peptide (TYSPALNKMF) monomeric recombinant protein is rooted in the fields of immunology and cancer research. HLA-A*24:02 is a widely expressed human leukocyte antigen (HLA) allele, significant in presenting tumor-associated antigens to T cells, thereby influencing immune responses in cancer patients, particularly in Asian populations where it has a higher prevalence. The WT-1 protein, a transcription factor associated with various cancers, including leukemia and solid tumors, contains specific peptide sequences, such as TYSPALNKMF, that are recognized by cytotoxic T lymphocytes (CTLs). The monomeric recombinant protein, consisting of HLA-A*24:02 and B2M, allows for the detailed study of peptide binding, T-cell receptor interactions, and immune evasion mechanisms in tumors. Understanding the dynamics of the WT-1 peptide presented by this HLA allele could lead to advancements in immunotherapeutic strategies, including vaccine design aimed at enhancing anti-tumor immunity. This research is critical for developing personalized cancer therapies and improving treatment outcomes for patients with HLA-A*24:02 positivity.
